The Innovation Consortium CureND was startet in July 2006 through a grant from the Danish Ministry of Science, Innovation and Technology. It consists of research groups from Aarhus University and Aalborg University as well as the pharmaceutical company Wyeth, with protein production provided by the service institute Bioneer. The general aim of CureND is to develop drugs to halt the progression of Parkinson’s Disease (based on an ability to halt the aggregation of α-synuclein), in parallel with the development of diagnostic approaches to identify early stage patients that may benefit particularly well from such treatment.
Biophysical techniques to monitor protein aggregation and protein-ligand interactions (plate readers, light scattering equipment, optical spectroscopy, quartz crystal microbalances, calorimetry).
In-depth experience of kinetic models of protein folding, misfolding and aggregation.
Proteomics facilities, including 2-D gel electrophoresis, state-of-the-art chromatography equipment and mass spectrometry.
Cell culture equipment and immunochemistry to analyze effects of protein aggregation in vivo.
Close collaboration with inSPIN centre on general aspects of protein aggregation.
Peter Reinhart (vice director, Wyeth Research), HTS and drug development, email@example.com
Jan J. Enghild, proteomics of Parkinson’s Disease, firstname.lastname@example.org
Daniel Otzen, email@example.com